Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005057 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
A Phase 1 study of Melanoma (Skin), sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Study locations
NCT00005057 is a Phase 1 study of Melanoma (Skin) that has completed, run by National Human Genome Research Institute (NHGRI). The trial reports 3 study locations across 2 states.
The verdict
NCT00005057, a Phase 1 study of Melanoma (Skin), has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3
- Study locations
Study Summary
RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have stage IV melanoma.
Conditions Studied
Interventions
- DRUG ganciclovir
- BIOLOGICAL adenovirus RSV-TK
Study Locations (3)
Maryland
- Clinical Genetherapy Branch - Bethesda
- Metabolism Branch - Bethesda
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005057
The ClinicalTrials.gov registry entry for NCT00005057 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Human Genome Research Institute (NHGRI), which has 185 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 2 interventions - of which ganciclovir is the first listed.
NCT00005057 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Texas.
Frequently Asked Questions
What is clinical trial NCT00005057 about?
NCT00005057 is a clinical study titled "Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma". RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have stage IV melanoma.
What is the current status of trial NCT00005057?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-03.
What conditions does trial NCT00005057 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00005057?
The interventions under investigation include: ganciclovir (DRUG), adenovirus RSV-TK (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005057?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005057 being conducted?
This trial has 3 study locations across Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.